What are the key drivers for quality?

Dr Martin Landray
University of Oxford
Need for reliable evidence from clinical trials

* Essential for appropriate decision making concerning the benefits and risks associated with clinical interventions.

* Decisions made in the absence of reliable evidence (either because relevant trials have never been performed or because those that have been performed were poorly designed or conducted) may harm individual patients and public health.
Criteria for a good trial

* Ask an IMPORTANT question

* Answer it RELIABLY
High quality clinical trials

Avoid errors that matter to decision making

* Human subjects protection
  * appropriate information & consent at each stage
  * safe administration & monitoring of investigational products
  * safe study procedures & investigations

* Reliability of results

* Wider environment
  * participants in other trials
  * public health (including patients not in trials)
  * physical environment
Reliable assessment of treatment effects

1. Recruitment
2. Randomization with Allocation Concealment
3. Compliance with allocated treatment
4. Capture of relevant events in appropriate detail
5. Analysis by allocated treatment
Impact of errors on the reliability of results

* **Random Errors**
  * affect the precision of estimates (adding “noise” and reducing statistical power), but will not introduce bias in either direction
  [Note: For equivalence assessments, random errors are counter-conservative]

* **Systematic Errors**
  * lead towards a particular decision
Key features for reliable assessment of moderate treatment effects

* Proper randomization
  * no foreknowledge of likely treatment allocation

* Relevant outcomes
  * sufficient numbers
  * recorded with appropriate accuracy
  * adequate timescale

* Appropriate follow-up
  * meaningful treatment difference
  * minimize post-randomization withdrawals
  * minimize loss to follow-up (e.g. after 1\textsuperscript{st} event occurs or study treatment stops)

* Unbiased ascertainment and analysis of study outcomes
  * focus on robustness of result, not precision of data points
  * comparisons with the randomized control group (except for assessing big effects on rare events)
  * avoid emphasis on subgroups and on non-randomized “on-treatment” analyses
Facilitating recruitment

* Protocol
  * Inclusion criteria
    * relevant to target population
    * at sufficient risk of the key outcomes
    * differentiate from participant characterization
  * Exclusion criteria
    * human subjects protection
      * focus on comorbidity, concomitant medication, consent
      * avoid unnecessary criteria (if you don’t study it, you’ll never know)

* Operations
  * Site selection
  * Pre-screening
RECRUITMENT:
Large-scale recruitment & restricted site numbers

- Pre-screening to identify potentially eligible individuals
- Use of electronic data records (where available)

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>UK Sites</td>
<td>88</td>
</tr>
<tr>
<td>Identify</td>
<td>300,000</td>
</tr>
<tr>
<td>Invite</td>
<td>230,000</td>
</tr>
<tr>
<td>Screen</td>
<td>24,000 (10%)</td>
</tr>
<tr>
<td>Consent</td>
<td>16,000 (7%)</td>
</tr>
<tr>
<td>Randomized</td>
<td>8,000 (3%)</td>
</tr>
<tr>
<td>(per site)</td>
<td>~90</td>
</tr>
</tbody>
</table>
Value of pre-screening

Complete Enrolment (7000 participants):
Projected: 15 months
Complete Enrolment (7000 participants):
Projected: 15 months
Actual: 7 months
Sufficient numbers of relevant events

* Number of events, not participants, is chief determinant of power

* Composite outcomes that combine events which may involve different directions of effect are less sensitive and generalizable (e.g. total mortality, or total cancer)

* Treatment effects (hazards & benefits) may emerge at different time points
Direction of effect on all-cause mortality depends on proportions of vascular & non-vascular death.
Unbiased treatment allocation & follow-up

- No foreknowledge of likely treatment allocation
- Meaningful treatment difference
- Minimize post-randomisation withdrawals (i.e. intent-to-treat)
- Minimize losses to follow-up (e.g. after primary event occurs or study treatment stops)
Biased (i.e. non-randomized) follow-up & analysis

<table>
<thead>
<tr>
<th></th>
<th>Active</th>
<th>Placebo</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomized</td>
<td>6481</td>
<td>6536</td>
<td></td>
</tr>
<tr>
<td>Not willing/ineligible</td>
<td>117</td>
<td>159</td>
<td>0.02</td>
</tr>
<tr>
<td>Received treatment</td>
<td>6364</td>
<td>6377</td>
<td></td>
</tr>
<tr>
<td>Withdrew consent</td>
<td>343</td>
<td>396</td>
<td>0.05</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>367</td>
<td>369</td>
<td>&gt;0.05</td>
</tr>
</tbody>
</table>

Comparison of the 6364 versus 6377 who received treatment described as having been “Analyzed by intention-to-treat”

SUVIMAX Arch Intern Med 2004
### Impact of non-compliance

<table>
<thead>
<tr>
<th>Treatment effect on biomarker</th>
<th>Anticipated relative risk reduction</th>
<th>Active (n=4000)</th>
<th>Control (n=4000)</th>
<th>Power at p=0.01</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.0</td>
<td>20%</td>
<td>480 (12.0%)</td>
<td>600 (15.0%)</td>
<td>91%</td>
</tr>
<tr>
<td>0.7</td>
<td>14%</td>
<td>516 (12.9%)</td>
<td>600 (15.0%)</td>
<td>54%</td>
</tr>
</tbody>
</table>

Not to check these assumptions may have adverse public health implications
Avoid undue emphasis on data points

Reliable RESULT ≠ High quality DATA

High quality DATA ≠ Reliable RESULT
<table>
<thead>
<tr>
<th>Type of event</th>
<th>Simvastatin allocation</th>
<th>Placebo allocation</th>
<th>Risk ratio &amp; 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n=10269)</td>
<td>(n=10267)</td>
<td>Simvastatin better</td>
</tr>
<tr>
<td><strong>Coronary events</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal MI</td>
<td>357 (3.5%)</td>
<td>574 (5.6%)</td>
<td>0.62 (0.54–0.70)</td>
</tr>
<tr>
<td>Coronary death</td>
<td>587 (5.7%)</td>
<td>707 (6.9%)</td>
<td>0.82 (0.74–0.92)</td>
</tr>
<tr>
<td>Any coronary event</td>
<td>898 (8.7%)</td>
<td>1212 (11.8%)</td>
<td>0.73 (0.67–0.79)</td>
</tr>
<tr>
<td><strong>Strokes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal stroke</td>
<td>366 (3.6%)</td>
<td>499 (4.9%)</td>
<td>0.72 (0.63–0.83)</td>
</tr>
<tr>
<td>Fatal stroke</td>
<td>96 (0.9%)</td>
<td>119 (1.2%)</td>
<td>0.80 (0.61–1.05)</td>
</tr>
<tr>
<td>Any stroke</td>
<td>444 (4.3%)</td>
<td>585 (5.7%)</td>
<td>0.75 (0.66–0.85)</td>
</tr>
<tr>
<td><strong>Revascularisations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary</td>
<td>513 (5.0%)</td>
<td>725 (7.1%)</td>
<td>0.70 (0.62–0.78)</td>
</tr>
<tr>
<td>Non-coronary</td>
<td>450 (4.4%)</td>
<td>532 (5.2%)</td>
<td>0.84 (0.74–0.95)</td>
</tr>
<tr>
<td>Any revascularisation</td>
<td>939 (9.1%)</td>
<td>1205 (11.7%)</td>
<td>0.76 (0.70–0.83)</td>
</tr>
<tr>
<td><strong>ANY MAJOR VASCULAR EVENT</strong></td>
<td>2033 (19.8%)</td>
<td>2585 (25.2%)</td>
<td>0.76 (0.72–0.81)</td>
</tr>
</tbody>
</table>
### HPS: Effects of simvastatin-allocation on ADJUDICATED major vascular events

#### Type of event

<table>
<thead>
<tr>
<th>Type of event</th>
<th>Simvastatin allocation</th>
<th>Placebo allocation</th>
<th>Risk ratio &amp; 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Coronary events</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal MI</td>
<td>492 (4.8%)</td>
<td>743 (7.2%)</td>
<td>0.65 (0.58–0.73)</td>
</tr>
<tr>
<td>Coronary death</td>
<td>547 (5.3%)</td>
<td>687 (6.7%)</td>
<td>0.79 (0.71–0.88)</td>
</tr>
<tr>
<td>Any coronary event</td>
<td>988 (9.6%)</td>
<td>1350 (13.1%)</td>
<td>0.72 (0.66–0.78)</td>
</tr>
<tr>
<td><strong>Strokes</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-fatal stroke</td>
<td>487 (4.7%)</td>
<td>621 (6.0%)</td>
<td>0.77 (0.69–0.87)</td>
</tr>
<tr>
<td>Fatal stroke</td>
<td>82 (0.8%)</td>
<td>105 (1.0%)</td>
<td>0.78 (0.58–1.03)</td>
</tr>
<tr>
<td>Any stroke</td>
<td>550 (5.4%)</td>
<td>700 (6.8%)</td>
<td>0.77 (0.69–0.87)</td>
</tr>
<tr>
<td><strong>Revascularisations</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coronary</td>
<td>487 (4.7%)</td>
<td>667 (6.5%)</td>
<td>0.72 (0.64–0.81)</td>
</tr>
<tr>
<td>Non-coronary</td>
<td>492 (4.8%)</td>
<td>559 (5.4%)</td>
<td>0.87 (0.77–0.98)</td>
</tr>
<tr>
<td>Any revascularisation</td>
<td>943 (9.2%)</td>
<td>1166 (11.4%)</td>
<td>0.79 (0.73–0.86)</td>
</tr>
<tr>
<td><strong>ANY MAJOR VASCULAR EVENT</strong></td>
<td>2187 (21.3%)</td>
<td>2765 (26.9%)</td>
<td>0.77 (0.72–0.81)</td>
</tr>
</tbody>
</table>
Improve study conduct by better design (not by finding problems retrospectively)

* Practical protocols are more likely to succeed
  * e.g. integration with usual clinical pathways, clear & feasible procedures

* Maximize recruitment & minimize sites/countries

* Select location based on feasibility

* IT can do more than just capture data

* Tailor monitoring/oversight to detect potential issues

* Relevant training & mentor staff based on their role
Quality by Design (QbD)

Protocol (Plan)
- assess key risks (likelihood, impact)
- plan mitigation
- plan evaluation

Operations (Do)
- organization, training, systems and procedures tailored to the protocol

Monitoring (Check)
- measure and evaluate performance

Make improvements (Act)
- re-assess risks
- make appropriate changes to protocol, operations or monitoring

Landray et al in press
Conclusions

* Objective: Improve the availability of reliable information on for important healthcare decisions

* Design quality in to the trial protocol and procedures

* Identify and address risks as trial progresses

* Focus efforts to enhance quality (including monitoring):
  * Appropriate to the setting
  * Proportionate to the risks
  * Foster improvement

* Be open about quality assurance
  * Share management plans and issues identified